Search Within

Christopher A Famulare

  1. "Meeting abstract"
Formats
  1. Meeting Abstract (47)
Groups
  1. Center for Hematologic Malignancies (47)
  2. Department of Medicine (45)
  3. Hematologic Malignancies, Division of (45)
  4. Adult Leukemia (44)
  5. GSK Faculty (30)
  6. Weinberg Fellows (29)

More Groups

People
  1. Ross Levine (27)
  2. Martin Tallman (21)
  3. Aaron Goldberg (20)
  4. Jacob Glass (15)
  5. Raajit Rampal (15)
  6. Kamal Menghrajani (14)

More People

Years
  1. 2024 (1)
  2. 2023 (5)
  3. 2022 (3)
  4. 2021 (4)
  5. 2020 (8)
  6. 2019 (9)

More Years

Publications
  1. Blood (44)
  2. Laboratory Investigation (2)
  3. Clinical Lymphoma, Myeloma and Leukemia (1)
Publishers
  1. American Society of Hematology (44)
  2. Nature Publishing Group (2)
  3. Elsevier Inc. (1)

Results (47)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PHF6 mutations are mutually exclusive to TP53 mutations, and define a distinct subgroup of secondary acute myeloid leukemia associated with a primitive stem/progenitor immunophenotype, absent complex karyotype and relatively better outcomes
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Ball, B.; Famulare, C.; Pastore, F.; Tallman, M. S.; Zhang, Y.; Arcila, M. E.; Papaemmanuil, E.; Levine, R. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for persistent measurable residual disease and poor outcomes in acute myeloid leukemia
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Famulare, C.; Delvin, S.; Patel, M.; McGovern, E.; Patel, A.; Schulman, J.; Dunbar, A.; Epstein-Peterson, Z. D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Myeloproliferative neoplasm (MPN) blastic transformation occurs at the level of hematopoietic stem cells
    Meeting Abstract

    Wang, X.; Hu, C. S.; Tripodi, J.; Najfeld, V.; Petersen, B.; Rampal, R. K.; Farnoud, N.; Famulare, C.; Mascarenhas, J.; Hoffman, R.
    Blood (2018)

    Fulltext@MSK | Save
  • Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy
    Meeting Abstract

    Talati, C.; Goldberg, A. D.; Przespolewski, A.; Chan, O.; Al Ali, N.; Famulare, C.; Sallman, D. A.; Padron, E.; Kuykendall, A.; List, A. F.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Genomic landscape impacts induction outcome with CPX-351 in patients with acute myeloid leukemia
    Meeting Abstract

    Talati, C.; Goldberg, A. D.; Desai, P.; Chan, O.; Famulare, C.; Komrokji, R. S.; Kuykendall, A. T.; Fernandez, H. F.; Deutsch, Y. E.; Padron, E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Prognostic impact of activating mutations of the NRAS/KRAS genes in patients with primary and post-essential thrombocythemia (ET)/polycythemia vera (PV) myelofibrosis (MF)
    Meeting Abstract

    Santos, F. P. S.; Getta, B.; Masarova, L.; Famulare, C.; Schulman, J.; Puga, R. D.; Paiva, R. D. A.; Hamerschlak, N.; Kantarjian, H. M.; Levine, R. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A novel prognostic model including cytogenetic and molecular data in patients with primary and post-essential thrombocythemia (ET)/polycythemia vera (PV) myelofibrosis (MF)
    Meeting Abstract

    Santos, F. P. S.; Getta, B.; Masarova, L.; Famulare, C.; Schulman, J.; Datoguia, T. S.; Goncalves, G. A. R.; Hamerschlak, N.; Kantarjian, H. M.; Levine, R. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia
    Meeting Abstract

    Goldberg, A. D.; Talati, C.; Desai, P.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Sallman, D. A.; Lancet, J. E.; Roboz, G. J.; Sweet, K. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Alisertib (MLN8237), an oral selective inhibitor of aurora kinase A, has clinical activity and restores GATA1 expression in patients with myelofibrosis
    Meeting Abstract

    Gangat, N.; Stein, B. L.; Marinaccio, C.; Swords, R.; Watts, J. M.; Gurbuxani, S.; Frankfurt, O.; Altman, J. K.; Wen, J. Q.; Farnoud, N.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Molecular predictors and current management of minimal residual disease (MRD) following induction chemotherapy for acute myeloid leukemia (AML)
    Meeting Abstract

    Goldberg, A. D.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Menghrajani, K.; Patel, M.; Cai, S.; Dunbar, A.; Epstein-Peterson, Z. D.; McGovern, E.; more...
    Blood (2018)

    Fulltext@MSK | Save